William Blair Weighs in on CVRx’s Q2 Earnings (NASDAQ:CVRX)

CVRx, Inc. (NASDAQ:CVRX) – William Blair lowered their Q2 2025 earnings per share estimates for shares of CVRx in a research report issued on Wednesday, February 5th. William Blair analyst M. Andrew now forecasts that the company will earn ($0.54) per share for the quarter, down from their prior estimate of ($0.50). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.61) per share. William Blair also issued estimates for CVRx’s Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($2.06) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.92) EPS.

CVRx (NASDAQ:CVRX) last issued its earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%.

A number of other equities analysts have also recently issued reports on CVRX. Lake Street Capital increased their target price on CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Piper Sandler increased their price target on CVRx from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and set a $14.00 price target on shares of CVRx in a research report on Wednesday, October 23rd. Craig Hallum increased their price target on CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Finally, Canaccord Genuity Group increased their price target on CVRx from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, CVRx presently has an average rating of “Moderate Buy” and a consensus target price of $17.83.

CVRx Trading Down 0.5 %

Shares of CVRX opened at $14.64 on Friday. CVRx has a 1 year low of $6.40 and a 1 year high of $24.75. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76. The stock has a 50 day simple moving average of $14.68 and a 200-day simple moving average of $11.78. The stock has a market cap of $355.17 million, a PE ratio of -5.42 and a beta of 1.29.

Institutional Investors Weigh In On CVRx

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of CVRx in the 3rd quarter valued at $108,000. Calamos Advisors LLC acquired a new stake in shares of CVRx in the 4th quarter valued at $134,000. XTX Topco Ltd acquired a new stake in shares of CVRx in the 3rd quarter valued at $150,000. Jane Street Group LLC increased its stake in shares of CVRx by 36.1% in the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock valued at $168,000 after buying an additional 5,053 shares during the period. Finally, Barclays PLC increased its stake in shares of CVRx by 312.5% in the 3rd quarter. Barclays PLC now owns 19,067 shares of the company’s stock valued at $169,000 after buying an additional 14,445 shares during the period. 75.27% of the stock is owned by institutional investors and hedge funds.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.